2.4.0.8 Html 90 223 1 false 36 0 false 7 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.merrimackpharma.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.merrimackpharma.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.merrimackpharma.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.merrimackpharma.com/taxonomy/role/StatementOfOtherComprehensiveIncome Condensed Consolidated Statements of Comprehensive Loss false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.merrimackpharma.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows false false R6.htm 107 - Disclosure - Nature of the Business Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Nature of the Business false false R7.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Summary of Significant Accounting Policies false false R8.htm 109 - Disclosure - Net Loss Per Common Share Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss Per Common Share false false R9.htm 110 - Disclosure - License and Collaboration Agreements Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock License and Collaboration Agreements false false R10.htm 111 - Disclosure - Fair Value of Financial Instruments Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Instruments false false R11.htm 112 - Disclosure - Accounts Payable, Accrued Expenses and Other Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accounts Payable, Accrued Expenses and Other false false R12.htm 113 - Disclosure - Borrowings Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Borrowings false false R13.htm 114 - Disclosure - Common Stock Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Common Stock false false R14.htm 115 - Disclosure - Stock-Based Compensation Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation false false R15.htm 116 - Disclosure - Commitments and Contingencies Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R16.htm 117 - Disclosure - Subsequent Events Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events false false R17.htm 118 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) false false R18.htm 119 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) false false R19.htm 120 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss Per Common Share (Tables) false false R20.htm 121 - Disclosure - License and Collaboration Agreements (Tables) Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables License and Collaboration Agreements (Tables) false false R21.htm 122 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value of Financial Instruments (Tables) false false R22.htm 123 - Disclosure - Accounts Payable, Accrued Expenses and Other (Tables) Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accounts Payable, Accrued Expenses and Other (Tables) false false R23.htm 124 - Disclosure - Borrowings (Tables) Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables Borrowings (Tables) false false R24.htm 125 - Disclosure - Common Stock (Tables) Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Common Stock (Tables) false false R25.htm 126 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.merrimackpharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) false false R26.htm 127 - Disclosure - Nature of the Business - Additional Information (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureNatureOfTheBusinessAdditionalInformation Nature of the Business - Additional Information (Detail) false false R27.htm 128 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) false false R28.htm 129 - Disclosure - Summary of Significant Accounting Policies - Schedule of Non-Controlling Interest in Subsidiary (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNonControllingInterestInSubsidiary Summary of Significant Accounting Policies - Schedule of Non-Controlling Interest in Subsidiary (Detail) false false R29.htm 130 - Disclosure - Summary of Significant Accounting Policies - Schedule of Available-for-Sale Securities, All of Which Have Maturities of Twelve Months or Less (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAvailableforSaleSecuritiesAllOfWhichHaveMaturitiesOfTwelveMonthsOrLess Summary of Significant Accounting Policies - Schedule of Available-for-Sale Securities, All of Which Have Maturities of Twelve Months or Less (Detail) false false R30.htm 131 - Disclosure - Summary of Significant Accounting Policies - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAvailableforSaleSecuritiesInAnUnrealizedLossPosition Summary of Significant Accounting Policies - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Detail) false false R31.htm 132 - Disclosure - Net Loss Per Common Share - Additional Information (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformation Net Loss Per Common Share - Additional Information (Detail) false false R32.htm 133 - Disclosure - Net Loss Per Common Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageShares Net Loss Per Common Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares (Detail) false false R33.htm 134 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation License and Collaboration Agreements - Additional Information (Detail) false false R34.htm 135 - Disclosure - License and Collaboration Agreements - Schedule of Revenue Recognized and Assets and Liabilities under Collaborative Arrangements (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsScheduleOfRevenueRecognizedAndAssetsAndLiabilitiesUnderCollaborativeArrangements License and Collaboration Agreements - Schedule of Revenue Recognized and Assets and Liabilities under Collaborative Arrangements (Detail) false false R35.htm 136 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasis Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) false false R36.htm 137 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation Fair Value of Financial Instruments - Additional Information (Detail) false false R37.htm 138 - Disclosure - Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOther Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail) false false R38.htm 139 - Disclosure - Borrowings - Schedule of Future Minimum Payments under the Loans Payable (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureBorrowingsScheduleOfFutureMinimumPaymentsUnderTheLoansPayable Borrowings - Schedule of Future Minimum Payments under the Loans Payable (Detail) false false R39.htm 140 - Disclosure - Borrowings - Additional Information (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation Borrowings - Additional Information (Detail) false false R40.htm 141 - Disclosure - Common Stock - Additional Information (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureCommonStockAdditionalInformation Common Stock - Additional Information (Detail) false false R41.htm 142 - Disclosure - Common Stock - Schedule of Shares Reserved for Future Issuance (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureCommonStockScheduleOfSharesReservedForFutureIssuance Common Stock - Schedule of Shares Reserved for Future Issuance (Detail) false false R42.htm 143 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) false false R43.htm 144 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployees Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail) false false R44.htm 145 - Disclosure - Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRecognizedStockBasedCompensationExpense Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation Expense (Detail) false false R45.htm 146 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivity Stock-Based Compensation - Summary of Stock Option Activity (Detail) false false R46.htm 147 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false R47.htm 148 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.merrimackpharma.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) false false All Reports Book All Reports Element us-gaap_ResearchAndDevelopmentExpense had a mix of decimals attribute values: -5 -3. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '128 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '134 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '140 - Disclosure - Borrowings - Additional Information (Detail)' had a mix of different decimal attribute values. 'Shares' elements on report '141 - Disclosure - Common Stock - Additional Information (Detail)' had a mix of different decimal attribute values. 'Shares' elements on report '143 - Disclosure - Stock-Based Compensation - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 105 - Statement - Condensed Consolidated Statements of Comprehensive Loss Process Flow-Through: 106 - Statement - Condensed Consolidated Statements of Cash Flows mack-20140331.xml mack-20140331.xsd mack-20140331_cal.xml mack-20140331_def.xml mack-20140331_lab.xml mack-20140331_pre.xml true true